Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used in the general population for treating pain and inflammatory conditions ([@b11-tcrm-4-983]). They comprise traditional (t) NSAIDs and NSAIDs selective for cyclooxygenase (COX)-2 (named coxibs) which were developed to reduce the risk of serious gastrointestinal (GI) complications -- dependent, at least in part, on the inhibition of COX-1 ([@b20-tcrm-4-983]). The therapeutic effects (analgesic and anti-inflammatory) of NSAIDs, both traditional and coxibs, are mostly due to the inhibition of COX-2-dependent prostanoids ([Figure 1A](#f1-tcrm-4-983){ref-type="fig"}). In placebo-controlled randomized clinical trials (RCTs), coxibs (rofecoxib \[Vioxx®\], celecoxib \[Celebrex®, Artilog®, Solexa®, Artrid®\] and valdecoxib \[Bextra®\]) were associated with an increase in the relative risk (RR) of cardiovascular (CV) events by 1- to 2.7-fold ([@b48-tcrm-4-983]; [@b9-tcrm-4-983]; [@b77-tcrm-4-983]; [@b58-tcrm-4-983]; [@b47-tcrm-4-983]). However, the results of observational studies and a meta-analysis of data derived from trials with coxibs have shown that the CV hazard is not restricted to NSAIDs selective for COX-2 but also applies to some tNSAIDs, such as diclofenac ([@b25-tcrm-4-983]; [@b32-tcrm-4-983]). In a recent nested-case control study, we found that patients taking NSAIDs (both coxibs and tNSAIDs) had a 35% increased risk of myocardial infarction ([@b55-tcrm-4-983]). Clinical results suggest that the CV hazard associated with the administration of NSAIDs is dose-dependent ([@b55-tcrm-4-983]; [@b78-tcrm-4-983]). In addition, the genetic background of the individual may play a role in increased susceptibility to inhibition of NSAIDs ([@b4-tcrm-4-983]). To limit the possible detrimental effects, associated with the administration of this efficacious class of drugs, is necessary to develop strategies of risk management through the identification of genetic and biochemical markers to select the responders to NSAIDs or who are uniquely susceptible to developing thrombotic or GI events by COX inhibition.

Differential COX pathways are effective in health and disease
=============================================================

Biology of COX-1 and COX-2
--------------------------

Prostanoids are lipid autacoids -- including prostaglandin (PG) E~2~, PGF~2α~, PGD~2~, prostacyclin (PGI~2~), and thromboxane(TX) A~2~ -- that are immediately released outside the cell after intracellular biosynthesis and modulate a wide variety of physiologic and pathologic processes via the interaction with specific receptors expressed mostly on the surface of target cells ([@b46-tcrm-4-983]; [@b10-tcrm-4-983]).

Under normal physiologic conditions, prostanoids play an essential homeostatic role in the GI cytoprotection, hemostasis, renal physiology, gestation, and parturition ([@b22-tcrm-4-983]; [@b57-tcrm-4-983]; [@b21-tcrm-4-983]). Moreover, they play important roles in pathophysiologic processes such as inflammation, cancer, and thrombosis ([@b22-tcrm-4-983]; [@b57-tcrm-4-983]; [@b21-tcrm-4-983]). Two isoforms of COX (COX-1 and COX-2) have been cloned and characterized ([@b75-tcrm-4-983]). COX-1 and COX-2 are the products of different genes. COX-1 is considered a "housekeeping gene" by virtue of constitutive low-levels of expression in most cell types. However, high levels of constitutive expression of COX-1 have been detected in the stomach, platelets, and the kidney. In addition, COX-1 can be regulated during development ([@b68-tcrm-4-983]). In contrast, the gene for COX-2 is a primary response gene with many regulatory sites; thus, COX-2 expression can be rapidly induced by bacterial endotoxin (LPS), cytokines, such as interleukin (IL)-1β and tumor necrosis factor-α, growth factors, and the tumor promoter phorbol myristate acetate (PMA) (reviewed by [@b28-tcrm-4-983]). However, COX-2 is constitutively expressed in some cells in lung ([@b6-tcrm-4-983]), brain ([@b87-tcrm-4-983]; [@b31-tcrm-4-983]), kidney ([@b24-tcrm-4-983]), pancreatic β-cells ([@b67-tcrm-4-983]), and GI carcinomas ([@b65-tcrm-4-983]; [@b73-tcrm-4-983]; [@b16-tcrm-4-983]).

COX-1 and COX-2 share the same catalytic activities: the cyclooxygenase which oxidizes arachidonic acid (AA) to PGG~2~ and the peroxidase which reduces PGG~2~ to the unstable endoperoxide PGH~2~, precursor of prostanoids ([@b76-tcrm-4-983]) ([Figure 1B](#f1-tcrm-4-983){ref-type="fig"}). Although the peroxidase reaction is considered the second step in the formation of PGH~2~, the COX reaction is absolutely dependent on peroxidase activity for its activation ([@b37-tcrm-4-983]). However, the two COX-isozymes require different levels of hydroperoxides to initiate cyclooxygenase catalysis, ie, COX-2 requires considerably lower levels of hydroperoxides than COX-1 ([@b34-tcrm-4-983]; [@b38-tcrm-4-983]). Elegant work performed by Funk's group reveals that COX-1 can partially compensate for COX-2 function but that this is limited by the differential ability of these two isoforms to metabolize low concentrations of arachidonate ([@b88-tcrm-4-983]). In fact, COX-2 catalysis occurs at lower levels of free AA than COX-1 ([@b79-tcrm-4-983]).

These differences in the regulation of COX-1 and COX-2 catalysis contribute to the development of cell-specific pathways of prostanoid biosynthesis dominated by one or the other enzyme in vivo even in the presence of the concurrent expression of the 2 isozymes ([@b14-tcrm-4-983]). As an example, in endothelial cells where different antioxidant defence systems are operative to maintain a reductive cytosolic environment, COX-2 is the dominant pathway turned on to generate prostacyclin, an important anti-atherogenic and anti-thrombotic mediator ([@b23-tcrm-4-983]) ([Figure 2](#f2-tcrm-4-983){ref-type="fig"}).

COX-2 is the major pathway in pain
----------------------------------

Other than in inflammation and pyresis, COX-2 plays an important role in nociception ([@b83-tcrm-4-983]). Noxious stimuli (eg, physical, chemical, thermal) in peripheral tissues cause damage and the inflammatory response leads to the release of pain-producing substances that activate nociceptors on the terminals of sensory nerve fibers. This pain is the hallmark of protective response to adverse stimuli and subsides with removal of the stimulus. In this context, the induction of COX-2, leading to enhanced prostanoid release, translates into sensitization of peripheral nociceptor terminals and produces localized pain hypersensitivity. In fact, prostanoids increase neuronal activity in nociceptive nerve fibers by raising cAMP levels and lowering the activation threshold for opening of tetrodotoxin-resistant sodium channels in the neuronal membrane. PGE~2~ and prostacyclin, produced in the peripheral terminals of sensory nerve endings, are hyperalgesic and enhance nociception produced by other mediators (such as bradykinin) ([@b43-tcrm-4-983]; [@b44-tcrm-4-983]). Moreover, peripheral inflammation also generates pain hypersensitivity in neighboring uninjured tissue (secondary hyperalgesia), because of increased neuronal excitability in the spinal cord (central sensation) and a syndrome comprising diffuse muscle and joint pain, fever, lethargy, and anorexia ([@b70-tcrm-4-983]). NSAIDs play an antinociceptive action by acting both at peripheral sites and at central sites mainly through COX-2 inhibition. Both COX-1 mRNA and COX-2 mRNA as well as COX-1 and COX-2 proteins are expressed constitutively in the spinal cord but only COX-2 can be induced in response to exogenous and endogenous cytokines ([@b7-tcrm-4-983]; [@b27-tcrm-4-983]; [@b82-tcrm-4-983]). Like nociceptive pain, hyperalgesia is linked to an adverse stimulus and diminishes with healing and decreased inflammation. Prolonged acute pain and hyperalgesia, however, can evolve into chronic pain.

The results of RCTs showing a comparable pain relief by NSAIDs selective for COX-2 and tNSAIDs both in acute clinical pain models (for example, oral surgery) and chronic clinical pain models (such as osteoarthritis \[OA\] and inflammatory arthropaties), support a major role of inhibition of COX-2 in their clinical efficacy ([@b20-tcrm-4-983]; [@b71-tcrm-4-983]). However, it should be pointed out that often the RCTs, comparing tNSAIDs and coxibs, had inadequate power to detect small differences possibly associated with inhibition of COX-1. Mostly, they were sized to detect equivalence, not superiority, of either ([@b57-tcrm-4-983]).

COX-1 is the major pathway in GI protection
-------------------------------------------

Prostanoids (PGE~2~ and prostacyclin) are key mediators to maintain gastric mucosal blood flow and increase protective mucus as well as bicarbonate production ([@b86-tcrm-4-983]). Several lines of evidence show that prostanoids produced in normal GI tissue which are required for normal physiological functioning are derived from the COX-1 isoform ([@b29-tcrm-4-983]). However, upregulation of COX-2 in the margin of healing ulcers and evidence from the use of COX inhibitors in rodents has raised concerns that COX-2 might be involved in the healing of existing ulcers ([@b74-tcrm-4-983]; [@b81-tcrm-4-983]). However, COX-2 up-regulation in the GI tract has been observed in cancer development ([@b69-tcrm-4-983]; [@b59-tcrm-4-983]; [@b45-tcrm-4-983]; [@b84-tcrm-4-983]).

COX-1 is involved in TXA~2~-dependent platelet function
-------------------------------------------------------

Platelets generate TXA~2~ from AA through the activity of COX-1 ([@b54-tcrm-4-983]). TXA~2~ generated in response to a variety of stimuli (for example, collagen, thrombin, and adenosine diphosphate) participates in the control of hemostasis through the induction of irreversible platelet aggregation triggered by the interaction with G-protein--coupled receptors, the TXA~2~ receptors ([@b2-tcrm-4-983]). Recent findings show that tiny concentrations of TXA~2~ can cause platelet activation ([@b41-tcrm-4-983]; [@b60-tcrm-4-983]; [@b40-tcrm-4-983]). Thus, 10 nM of the TXA~2~ mimetic U46619 induces platelet adhesion and shape change ([@b41-tcrm-4-983]), and in the presence of a subthreshold concentration of collagen it causes platelet aggregation ([@b60-tcrm-4-983]). Moreover, TXA~2~ causes vasoconstriction and vascular proliferation; thus, it is involved in atherogenesis and increase in blood pressure ([Figure 2](#f2-tcrm-4-983){ref-type="fig"}) ([@b23-tcrm-4-983]).

COX-2-dependent prostacyclin is the major pathway in vascular protection
------------------------------------------------------------------------

In vascular endothelial cells, COX-2 plays a dominant role in producing important prostanoids to regulate the functions of underlying vascular smooth muscle cells and circulating cells. Although endothelial cells may generate a different array of the prostanoids PGD~2~, PGE~2~, and prostacyclin along the vascular beds, there is robust evidence that prostacyclin is the dominant prostanoid produced in the macrocirculation ([@b42-tcrm-4-983]; [@b23-tcrm-4-983]).

Prostacyclin potently inhibits aggregation of platelets induced by TXA~2~ and other agonists, vascular smooth muscle cell proliferation and vascular tone, leukocyte--endo-thelial cell interactions, and cholesteryl ester hydrolase ([@b23-tcrm-4-983]). As shown in [Figure 2](#f2-tcrm-4-983){ref-type="fig"}, most of the deleterious effects of TXA~2~ in the CV system are countered by prostacyclin, mainly through the activity of COX-2. Thus, inhibition of vascular COX-2 leads to loss of the protective function associated with prostacyclin. Recently, it has been reported an antioxidant role for prostacyclin through the induction of hemoxygenase-1 ([@b19-tcrm-4-983]). For all these biological actions, prostacyclin has on the distinctive features of a cardioprotective mediator. Studies in knockout (KO) mice for prostacyclin receptor (IP) and the recent findings of acceleration of CV disease in humans by a dysfunctional IP mutation convincingly support the protective role of prostacyclin for the CV system ([@b4-tcrm-4-983]; [@b51-tcrm-4-983]).

Biochemical biomarkers of COX inhibition
----------------------------------------

NSAIDs are distinguished on the basis of their COX-isozyme selectivity in vitro, described as the ratio of the concentrations required to inhibit the activity of the isozymes by 50% (IC50 for COX-1/IC50 for COX-2) ([Figure 3A](#f3-tcrm-4-983){ref-type="fig"}). The assessment of COX-1/COX-2 ratios in vitro describes an experimental COX-isozyme selectivity which mirrors the chemical features of the different NSAIDs. This is assessed using the human whole blood assays which evaluate the effects of drugs on platelet COX-1 and monocyte COX-2 activities ([@b56-tcrm-4-983]; [@b52-tcrm-4-983]). They are capacity indexes of COX-isozyme activities to generate prostanoids from endogenous sources of AA and their pharmacological inhibition is not influenced by different pathological conditions. These assays are based on the measurement of PGE~2~ production, in response to lipopolysaccharide (LPS) added to heparinized human blood samples for 24 h which reflects the time-dependent induction of COX-2 in circulating monocytes ([@b52-tcrm-4-983]). The parallel measurement of TXB~2~ production during whole blood clotting is used as an index of platelet COX-1 activity ([@b56-tcrm-4-983]). When the COX-1/COX-2 IC~50~ ratio is higher than 1 the drug is more potent in inhibiting COX-2. When the ratio is approximately 1, the drug is a non-selective inhibitor of both COX-1 and COX-2. When the ratio is lower than 1, the drug is more potent towards COX-1. We assessed COX-1/COX-2 IC~50~ values of several COX inhibitors. Interestingly, we have found that the biochemical selectivity is a continuous variable preventing the separation of tNSAIDs from coxibs ([@b49-tcrm-4-983]). However, we can identify some drugs more selective for COX-1 than COX-2 (such as aspirin, naproxen and ibuprofen) from the wide cluster of agents more selective for COX-2 than COX-1. This includes: i) piroxicam and indomethacin which are approximately 3-fold more selective for COX-2; ii) etodolac, meloxican, diclofenac, celecoxib, and valdecoxib which are 6- to 60-fold more selective for COX-2; iii) the highly selective COX-2 inhibitors such as, etoricoxib, rofecoxib, and lumiracoxib which have a COX-1/COX-2 IC~50~ ratio higher than 100 ([Table 1](#t1-tcrm-4-983){ref-type="table"}).

The whole blood assays also enable estimation of achieved COX-isozyme selectivity in humans, which is the ratio of isozyme inhibition at a given plasma concentration ([Figure 3B](#f3-tcrm-4-983){ref-type="fig"}). Importantly, achieved selectivity of NSAIDs varies as a consequence of the dose administered.

There is evidence that the whole blood assays for COX-2 and COX-1 may be candidate surrogate end-points of efficacy and GI toxicity of NSAIDs, respectively. It has been shown that COX-2 inhibition, as determined by PGE~2~ levels in LPS-stimulated whole blood, can be used as a marker to predict drug efficacy in humans ([@b26-tcrm-4-983]). In fact, (concentration required to inhibit the activity of IC~80~ COX-2 by 80% in vitro) values have been found to correlate directly with the analgesic/anti-inflammatory plasma concentrations of different COX inhibitors ([@b26-tcrm-4-983]). Thus, COX-2 inhibition, by assessing PGE~2~ levels in the whole blood assay in vitro and ex vivo, can be used as a marker to predict drug effects (analgesia, antiinflammatory effects) in humans. Similarly, platelet COX-1 inhibition, by assessing TXB~2~ levels in the whole blood assay in vitro and ex vivo, can be used as a marker to predict toxicity or efficacy (GI toxicity or antiplatelet effects) in humans by NSAIDs. In fact, [@b18-tcrm-4-983] reported that the inhibitory effects of tNSAIDs on gastric PGE~2~ synthesis correlate with COX-1 inhibitory potency in clotting blood.

Now it is critical to establish the CV safety profile of specific individual NSAIDs, be it tNSAIDs or coxibs, and to find valid surrogate biochemical predictors of that risk.

Studies of clinical pharmacology have shown discordant functional implications of inhibition of COX-1 and COX-2. A linear relationship exists between the extent of inhibition of COX-2 and that of prostacyclin in vivo ([@b55-tcrm-4-983]). In contrast, inhibition of TXA~2~-dependent platelet function in vivo occurs when platelet COX-1-dependent capacity to synthesize TXA~2~ (as assessed by measuring serum TXB~2~ levels) is reduced ≥95% ([@b63-tcrm-4-983]). In fact, a non-linear relationship of inhibition of platelet TXA~2~ generation with inhibition of TXA~2~-mediated platelet aggregation has been found ([@b72-tcrm-4-983]). This is explained by the fact that even tiny concentrations of TXA~2~ may activate the platelets. [@b40-tcrm-4-983] have shown that low concentrations of TXA~2~ activate the tyrosine-kinase-based signaling pathway which may translate into a full platelet activation in the presence of weak platelet agonists or subthreshold concentrations of stronger agonists.

These findings lead to the concept of functional COX-2 selectivity by NSAIDs, ie, inhibition of COX-2 in the presence of an insufficient reduction of platelet COX-1 activity to translate into inhibition of platelet function. It has to be pointed out that most NSAIDs are functionally selective for COX-2 at therapeutic doses similarly to coxibs. The only tNSAID that has been shown to be functionally non-selective for the platelet is naproxen at high doses, in some individuals ([@b15-tcrm-4-983]). This depends on the fact that naproxen usually administered at high doses bid is more potent for COX-1 than COX-2, and it is characterized by a pharmacokinetic half-life of approx 14 h ([@b11-tcrm-4-983]). Thus, naproxen is associated with profound inhibition of prostacyclin but the possible CV hazard associated with this effect may be mitigated by a parallel profound and persistent suppression of platelet TXA~2~ ([@b15-tcrm-4-983]), which translates into a small CV protection or neutral effect ([@b25-tcrm-4-983]; [@b32-tcrm-4-983]).

Recent findings suggest that for functional non-selective NSAIDs the extent of inhibition of COX-2-dependent pros-tacyclin may predict the increased incidence of myocardial infarction (MI) ([@b55-tcrm-4-983]). Individual NSAIDs with a degree of COX-2 inhibition \<90% at therapeutic concentrations presented a RR of 1.18 (95% CI, 1.02--1.38) while those with a greater COX-2 inhibition had a RR of 1.60 (95% CI, 1.41--1.81).

Thus, it has been proposed that the assessment of whole blood COX-2 ex vivo -- alone or in combination with the measurement of urinary levels of 2,3-dinor-6- keto-PGF~1α~ \[a biomarker of prostacyclin biosynthesis in vivo ([Figure 4](#f4-tcrm-4-983){ref-type="fig"})\] -- in association with genetic biomarkers (such as polymorphisms in the prostacyclin receptor IP) ([@b4-tcrm-4-983]) may be surrogate end-points of CV hazard by pharmacological inhibition of COX-2 ([@b51-tcrm-4-983]).

Etoricoxib
----------

### Pharmacology

The NSAID selective for COX-2 etoricoxib, 5-chloro-6′-methyl-3-\[4-(methylsulfonyl) phenyl\]-2,3′-bipyridine ([Figure 5](#f5-tcrm-4-983){ref-type="fig"}) ([@b64-tcrm-4-983]) (Arcoxia^®^, Tauxib^®^, Algix^®^) has been approved in Europe, Latin America, and Asia-Pacific region for the treatment of OA, rheumatoid arthritis (RA), ankylosing spondylitis, acute gouty arthritis, acute pain, and chronic musculoskeletal pain, at doses ranging between 60 and 120 mg daily depending on the different indications.

As shown in [Figure 6A](#f6-tcrm-4-983){ref-type="fig"}, etoricoxib is 162-fold more potent towards COX-2 than COX-1 in the whole blood assay in vitro. The pharmacokinetics features of etoricoxib are reported in [Figure 6C](#f6-tcrm-4-983){ref-type="fig"} ([@b1-tcrm-4-983]). Importantly, it has a long half-life of 22 h and is metabolized via 6'-methyl hydroxylation in human liver microsomes. The reaction is catalyzed by a number of P450 forms, although CYP3A4 accounts for the majority (40%--90%) of the activity. The remainder of the activity is equally divided between a number of other P450s (eg, CYP2D6, CYP2C9, CYP1A2, and possibly CYP2C19). In this regard, the P450 reaction phenotype of etoricoxib is unique and differs from that of other COX inhibitors ([@b30-tcrm-4-983]).

As shown in [Figure 6B](#f6-tcrm-4-983){ref-type="fig"}, etoricoxib administered up to 120 mg is a selective COX-2 inhibitor. This result has been obtained by the extrapolation of COX-1 and COX-2 inhibition in vitro in the human whole blood assays by the maximal plasma concentration achieved after the administration of etoricoxib at single doses of 5, 10, 20, 40, 120 mg. Interestingly, an inhibition of COX-2 by 80% may be reached after the administration of 40 mg, suggesting that the dosage of the drug could be reduced without affecting efficacy. We performed studies of clinical pharmacology to assess achieved COX-2 selectivity ex vivo by the chronic administration of etoricoxib 90 mg daily versus the tNSAIDs diclofenac 75 mg bid, naproxen 500 mg bid, and aspirin 100 mg daily ([Figure 7 A--C](#f7-tcrm-4-983){ref-type="fig"}). As shown in [Figure 7A](#f7-tcrm-4-983){ref-type="fig"} the administration of etoricoxib (at 12 h after dosing), diclofenac (at 4 h after dosing), naproxen (at 12 h after dosing), and low-dose aspirin (at 24 h after dosing) caused a median inhibition of COX-1 of 1%, 60%, 95%, and 98%, respectively. These results show that inhibition of platelet COX-1 ≥95% (which translates into inhibition of platelet function) occurs in all subjected treated with low-dose aspirin and in some of those treated with high-dose naproxen, at the interval between doses, sustaining an anti-platelet effect of high-dose naproxen. In contrast, in all subjects treated with diclofenac and etoricoxib, the degree of inhibition of platelet COX-1 was not adequate to affect significantly TXA~2~-dependent platelet function. However, our results showed a marked inter-subject variability in the inhibition of platelet COX-1 after the administration of diclofenac (range 8--98%) and to a lesser extent also for etoricoxib (range 0%--48%). As shown in [Figure 7B](#f7-tcrm-4-983){ref-type="fig"}, whole blood COX-2 was profoundly affected by etoricoxib, diclofenac, and naproxen, but not by low-dose aspirin (median inhibition and range: 86% \[70--90\], 98% \[58--100\], 79% \[30--83\], and 0% \[0--31\], respectively\]. These data show that both diclofenac and etoricoxib were administered at supratherapeutic doses, in fact most of individuals had a COX-2 inhibition higher than 80%, considered sufficient to translate into efficacy. From these values we calculated the achieved selectivity (ie the ratio of COX-2 inhibition and COX-1 inhibition ex vivo). As shown in [Figure 7C](#f7-tcrm-4-983){ref-type="fig"}, for etoricoxib and diclofenac the individual values of achieved COX selectivity were placed above 1 (which represents a balanced inhibition of COX-2 and COX-1) showing that circulating concentrations of the two drugs caused a more profound inhibition of COX-2 than COX-1. In contrast, naproxen and aspirin caused a more profound inhibition of COX-1 than COX-2; in fact the ratio of COX-2 /COX-1 inhibition ex vivo was always lower than 1. These data clearly show that diclofenac and naproxen, despite being considered tNSAIDs, are significantly different in selectivity compared with COX-isozymes at therapeutic doses. Interestingly, the achieved selectivity was not different, in a statistically significant fashion, between etoricoxib and diclofenac. These results will be relevant for interpretation of the clinical results, for both efficacy and toxicity.

Prostanoids are autocoids that act in the proximity of the cell where they are generated. In fact, they are subjected to an intense metabolism which leads to inactivation of prostanoids. It proceeds through β-oxidation ω-oxidation, 15-hydroxy dehydrogenation, and double-bond reduction through enzymatic pathways in liver, kidney, and lung ([@b62-tcrm-4-983]; [@b66-tcrm-4-983]) ([Figure 4](#f4-tcrm-4-983){ref-type="fig"}). The assessment of major enzymatic metabolites of prostanoids represents an index of their systemic biosynthesis. Several lines of evidence support a dominant platelet origin (mostly COX-1-derived) of a major urinary enzymatic metabolite of TXB~2~, ie 11-dehydro-TXB~2~, while vasculature (mostly COX-2 derived) represents the dominant origin of a major urinary enzymatic metabolite of prostacyclin, ie, 2,3-dinor-6-keto-PGF~1α~ ([@b14-tcrm-4-983]).

In susceptible patients, inhibition of prostanoid generation by tNSAIDs and coxibs causes sodium retention with resulting edema and hypertension ([@b23-tcrm-4-983]). Similarly to thrombogenesis, COX-1 inhibition may mitigate the consequence of COX-2 inhibition in the kidney. This is compatible with a COX-2-dependent source of vasodilatory prostacyclin and COX-1-dependent origin of vasoconstrictors, like TXA~2~ in the kidney ([@b61-tcrm-4-983]; [@b23-tcrm-4-983]). We studied the impact of etoricoxib and naproxen on renal and systemic prostanoid biosynthesis by assessing 6-keto-PGF~1α~/TXB~2~ inhibition ratio and 2,3-dinor-6-keto-PGF~1α~/11-dehydro-TXB~2~ inhibition ratio, respectively, after the administration of the drugs ([Figure 8](#f8-tcrm-4-983){ref-type="fig"}).

As shown in [Figure 8 A and B](#f8-tcrm-4-983){ref-type="fig"}, etoricoxib caused a more profound inhibition of COX-2 than COX-1 both at renal and extrarenal sites. This is predictive of a CV hazard but of reduced GI toxicity by etoricoxib. In contrast, naproxen reduced more profoundly COX-1 both at renal and extrarenal sites ([Figure 8A and B](#f8-tcrm-4-983){ref-type="fig"}), which may translate into reduced CV but higher GI side effects.

### Etoricoxib and GI toxicity

The GI safety of etoricoxib has been assessed in the MEDAL (Multinational Etoricoxib vs Diclofenac Arthritis Long Term) Programme ([@b35-tcrm-4-983]). It was prospectively designed to pool data from 3 randomized, double-blind clinical trials: the MEDAL study, the Etoricoxib vs Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) study, and the EDGE II study. Patients with OA or RA aged 50 years or over were eligible for enrollment if they had a clinical diagnosis of OA of the knee, hip, hand, or spine, or a clinical diagnosis of RA that satisfied at least 4 of 7 of the American Rheumatism Association 1987 revised criteria ([@b5-tcrm-4-983]), and in the judgment of the investigator, would require chronic therapy with an NSAID. Thus, etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) were compared in 34,701 patients with OA or RA for upper GI clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding). As shown in [Table 2](#t2-tcrm-4-983){ref-type="table"}, there were significantly fewer upper GI clinical events with the COX-2 selective inhibitor etoricoxib than with the tNSAID diclofenac due to a decrease in uncomplicated events, but not in the more serious complicated events. Less inhibition of gastric COX-1 by etoricoxib than diclofenac (etoricoxib is a more COX-2 selective drug than diclofenac in vitro and ex vivo \[[@b53-tcrm-4-983]; [@b80-tcrm-4-983]\] \[[Figure 7](#f7-tcrm-4-983){ref-type="fig"}\]) may explain the reduced incidence of uncomplicated GI events. In contrast, the comparable rates of GI bleeding by the two drugs could be due to a similar impact on platelet COX-1, in some individuals, and on healing of gastric lesions. In fact, it has been shown that COX-2 plays an important role in the healing of gastric ulcers and that inhibition of COX-2 delays ulcer healing ([@b33-tcrm-4-983]). As shown in [Figure 7B](#f7-tcrm-4-983){ref-type="fig"}, etoricoxib and diclofenac have a comparable profound impact on COX-2 (\>80%).

In MEDAL, the use of low-dose aspirin and proton pump inhibitors (PPIs) was allowed. Analyzing the data in aspirin and non-aspirin populations, it has been found that etoricoxib reduced the risk of uncomplicated upper GI events compared with diclofenac in patients taking low-dose aspirin regularly, but the magnitude of the GI benefit decreased with low-dose-aspirin use (aspirin: hazard ratio 0.73, 95% CI 0.64--1.07 versus no-aspirin: 0.52, 0.38--0.71, p = 0.021) ([@b35-tcrm-4-983]). PPIs were used concomitantly for at least 75% of the study period by 40% of patients and treatment effects did not differ significantly in these individuals; however, significantly fewer patients discontinued etoricoxib than diclofenac due to dyspepsia, and this decrease was similar in patients who took PPIs, suggesting that the COX-2-selective inhibitor provided symptomatic benefit even in patients already taking a PPI ([@b35-tcrm-4-983]).

### Etoricoxib and CV toxicity

In placebo-controlled RCTs, coxibs (rofecoxib, celecoxib, and valdecoxib) were associated with increased RR of CV events (1.92--3.7) ([@b48-tcrm-4-983]; [@b9-tcrm-4-983]; [@b47-tcrm-4-983]; [@b58-tcrm-4-983]; [@b77-tcrm-4-983]). An overview of data derived from trials with coxibs suggests that MI predominates over stroke ([@b32-tcrm-4-983]). These results led the regulatory authorities such as the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) to restrict the use of these drugs ([@b49-tcrm-4-983]). However, the results of observational studies and a meta-analysis of data derived from trials with coxibs have shown that the CV hazard is also associated with some tNSAIDs, such as diclofenac ([@b25-tcrm-4-983]; [@b32-tcrm-4-983]). A plausible mechanism in increased risk of vascular events in individuals treated with NSAIDs selective for COX-2 and some tNSAIDs is the inhibition of COX-2-dependent prostacyclin unaccompanied by inhibition of COX-1-dependent TXA~2~ at functional range, ie \>95%. In fact, most tNSAIDs are as COX-2 selective as coxibs for platelet function. In addition, coxibs and tNSAIDs inhibit profoundly prostacyclin generation in vivo, as assessed by the measurement of urinary levels of a major enzymatic metabolite 2,3-dinor-6-keto-PGF~1α~ ([@b17-tcrm-4-983]; [@b39-tcrm-4-983]).

The CV hazard associated with the use of coxibs led to the voluntarily withdrawal from the US and EU market of rofecoxib and valdecoxib, in 2004 and 2005, respectively. Recently, the FDA has formally rejected manufacturer application for approval of etoricoxib as a prescription pain reliever. The FDA decision was influenced by the results of safety analyses from the MEDAL Program ([@b12-tcrm-4-983]). The authors reported that etoricoxib (60 or 90 mg daily, mean duration of therapy was 18 months) and diclofenac (150 mg daily, ie 50 mg tid or 75 mg bid) administered to OA or RA patients have comparable rates, constant over time, of thrombotic CV events ([@b12-tcrm-4-983]). Despite etoricoxib and diclofenac having different COX-2 selectivity in vitro, they are functional COX-2 selective for platelet function. The shared pharmacodynamic translates into comparable incidence of thrombotic events detected in MEDAL.

Aside from the platelet, the relationship between inhibition of prostaglandin formation and prostaglandin dependent function appears to be roughly linear in other cell types. In this context, even an incomplete inhibition of COX-1 might attenuate the functional effect derived from inhibition of COX-2-dependent prostacyclin. This may occur in the kidney where COX-2 is the source of vasodilatory prostacyclin and COX-1 is the source of vasoconstrictor TXA~2~ ([@b61-tcrm-4-983]; [@b23-tcrm-4-983]). This is sustained by the results of MEDAL where the selective COX-2 inhibitor etoricoxib caused a higher incidence of blood pressure than the less selective tNSAID diclofenac. However, the more pronounced signal from MI rather than stroke showed by the use of NSAIDs (traditional and selective for COX-2) suggests that thrombosis is the dominant component of the CV hazard and thus lesser degrees of selectivity are likely only to mitigate the hazard to a marginal extent.

Both EMEA and FDA and the American Heart Association ([@b3-tcrm-4-983]) issued the recommendations that selective COX-2 inhibitors are contraindicated in patients with ischemic heart disease and/or stroke, that they have to be avoided in patients with risk factors for coronary heart disease, and that all patients have to take the lowest effective dose for the shortest time necessary to control symptoms. Importantly, we have recently shown that the degree of COX-2 inhibition achieved by individual NSAIDs (an index of drug potency/exposure), that do not show functional suppression of platelet COX-1, is a determinant of the CV hazard associated with them ([@b55-tcrm-4-983], [@b49-tcrm-4-983]).

Thus, a possible approach to reduce the CV risk associated with etoricoxib will be to use the lowest effective dose. Studies of efficacy with lower doses of etoricoxib than those used in MEDAL seem to support this possible strategy. Etoricoxib 30 mg/day has been shown efficacious in OA compared with either ibuprofen 800 mg tid ([@b85-tcrm-4-983]) or diclofenac 50 mg tid ([@b36-tcrm-4-983]). Moreover, it has been recently assessed the efficacy of etoricoxib 30 mg daily versus the recommended therapeutic dose of celecoxib, 200 mg daily, in the treatment of OA patients ([@b8-tcrm-4-983]). The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Etoricoxib was non-inferior to celecoxib and both were superior to placebo (p \< 0.001) for all three outcomes. The authors suggested that etoricoxib 30 mg was at least as effective as celecoxib 200 mg and had similar safety in the treatment of OA of knee and hip. As shown in [Figure 6B](#f6-tcrm-4-983){ref-type="fig"}, etoricoxib 30 mg seems adequate to reduce whole blood COX-2 at a degree appropriate to translate into clinical efficacy. However, further studies of clinical pharmacology in patients with OA and RA should be performed to verify the impact of etoricoxib 30 mg on biochemical markers of COX inhibition, such as whole blood COX-2 and systemic and renal biosynthesis of prostacyclin and TXA~2~.

Conclusions
===========

NSAIDs are an important and efficacious class of drugs for the management of musculoskeletal symptoms. The development of NSAIDs selective for COX-2 -- to reduce the incidence of serious GI adverse effects compared with tNSAIDs mainly dependent on the inhibition of COX-1 in GI tract and platelets -- has unravelled the important protective role of COX-2 for the CV system, mainly through the generation of prostacyclin. In a recent nested-case control study, we found that patients taking NSAIDs (both coxibs and tNSAIDs) had a 35% increase risk of MI. The increased incidence of thrombotic events associated with profound inhibition of COX-2-dependent prostacyclin can be mitigated, even if not removed, by a complete suppression of platelet COX-1 activity. In fact, inhibition of TXA~2~-dependent platelet function occurs when platelet COX-1 activity, assessed ex vivo, is reduced ≥95% ([@b63-tcrm-4-983]). We have introduced the concept of functional COX-2 selectivity (ie, a profound suppression of COX-2 associated with insufficient inhibition of platelet COX-1 to cause inhibition of platelet function) which is a feature shared by most tNSAIDs and coxibs. We have recently shown that inhibition of COX-2 and the functional selectivity with which it is achieved is relevant to CV hazard from NSAIDs and relates to drug potency (exposure) ([@b55-tcrm-4-983], [@b49-tcrm-4-983]).

The development of genetic and biochemical markers will help to identify the responders to NSAIDs or who are uniquely susceptible at developing thrombotic or GI events by COX inhibition. This will lead to the development of individual responder approaches. We propose that the assessment of whole blood COX-2 ex vivo (alone or in combination with urinary 2,3-dinor-6-keto-PGF~1α~) may represent a valid surrogate end-point to predict CV risk for functionally selective COX-2 inhibitors. The use of these biochemical markers together with genetic biomarkers will help to select patients uniquely susceptible to developing CV risk through inhibition of COX-2-dependent-prostacyclin when exposed to NSAIDs. Their use can lead to a rational selection of doses for efficacy and will help to make decisions in risk management of tNSAIDs and NSAIDs selective for COX-2.
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![Pathways of prostanoid biosynthesis. (A) Prostanoids (PGE2, PGD2, PGF2α, PGI2, TXA2) are produced by COX-1 and COX-2 and specific synthases; (B) PGH2, generated by cyclooxygenase and peroxydase activity of COX, is then converted to prostanoids by the activity of different synthases.](tcrm-4-983f1){#f1-tcrm-4-983}

![Vascular prostacyclin counteracts the cardiovascular effects of platelet TXA2.](tcrm-4-983f2){#f2-tcrm-4-983}

![Assessment of COX-isoform selectivity in whole blood in vitro (A) and ex vivo (B).](tcrm-4-983f3){#f3-tcrm-4-983}

![Biosynthesis and metabolism of prostacyclin (PGI~2~) and thromboxane (TX) A~2~.\
**Abbreviations:** PGIS, prostacyclin synthase; TXS, TX synthase.](tcrm-4-983f4){#f4-tcrm-4-983}

![Chemical structure of etoricoxib: bipyridine with a methyl sulfone side chain 5-chloro-6′-methyl-3-\[4-(methylsulfonyl) phenyl\]-2,3′-bipyridine.](tcrm-4-983f5){#f5-tcrm-4-983}

![COX-2 selectivity of etoricoxib in human whole blood. (A) Concentration-response curves assessed in vitro; (B) degree of inhibition of COX-2 and COX-1 by peak plasma concentrations obtained after dosing with etoricoxib 5, 10, 20, 40, and 120 mg; (C) pharmacokinetics features of etoricoxib.](tcrm-4-983f6){#f6-tcrm-4-983}

![Whole blood COX-1 (A) and COX-2 (B) inhibition ex vivo after the chronic administration of etoricoxib 90 mg, diclofenac 75 mg bid, naproxen 500 mg bid, and aspirin 100 mg daily to humans; (C) achieved COX-2 selectivity by the drugs.](tcrm-4-983f7){#f7-tcrm-4-983}

![Effects of the chronic administration of etoricoxib 90 mg daily and naproxen 500 mg bid to humans on prostacyclin/TXA2 inhibition ratio in the kidney (by assessing their urinary non-enzymatic metabolites: 6-keto-PGF1α and TXB2, respectively) (A), versus systemic biosynthesis (by assessing their urinary enzymatic metabolites: PGIM = 2,3-dinor-6-keto-PGF1α \[a major urinary enzymatic metabolite of prostacyclin\] and TX-M = 11-dehydro-TXB2 \[a major enzymatic metabolite of TXA2\], respectively) (B).](tcrm-4-983f8){#f8-tcrm-4-983}

###### 

Biochemical selectivity, assessed as COX-1/COX-2 IC~50~ values of several COX inhibitors (derived from [@b55-tcrm-4-983])

  COX-inhibitors   COX-1/COX-2 IC~50~ values
  ---------------- -----------------------------------------------
  naproxen         0.49
  ibuprofen        0.56
  indomethacin     2.9
  piroxicam        3.1
  etodolac         5.6
  meloxicam        13.8
  diclofenac       24.4
  celecoxib        32
  valdecoxib       61[a](#tfn1-tcrm-4-983){ref-type="table-fn"}
  etoricoxib       162
  rofecoxib        255
  lumiracoxib      400[b](#tfn2-tcrm-4-983){ref-type="table-fn"}

COX-1/COX-2 IC~50~ ratio value from [@b13-tcrm-4-983].

COX-1/COX-2 IC~50~ ratio value from [@b52-tcrm-4-983].

###### 

Risk of GI events with etoricoxib and diclofenac in MEDAL study (derived from [@b35-tcrm-4-983])

  Type of GI events               Hazard ratio with etoricoxib vs diclofenac   95% CI       p
  ------------------------------- -------------------------------------------- ------------ ----------
  All upper-GI events             0.69                                         0.57--0.83   0.0001
  Uncomplicated upper-GI events   0.57                                         0.45--0.74   \<0.0001
  complicated upper-GI events     0.91                                         0.67--1.24   0.0001

**Abbreviations:** GI, gastrointestinal; MEDAL, Multinational Etoricoxib vs Diclofenac Arthritis Long Term.
